Description
IL-17F Monoclonal Antibody
| Catalog number: | B2015351 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 10 g |
| Molecular Weight or Concentration: | N/A |
| Supplied as: | Solution |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | L-17F Monoclonal antibody |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Mills KHG. IL-17 and IL-17-producing cells in protection versus pathology Nat Rev Immunol. 2023 Jan;23(1):38-54.
- Adams R, Maroof A, Baker T, Lawson ADG, Oliver R, Paveley R, Rapecki S, Shaw S, Vajjah P, West S, Griffiths M. Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F Front Immunol. 2020 Aug 21;11:1894.
- Reich K, Warren RB, Lebwohl M, Gooderham M, Strober B, Langley RG, Paul C, De Cuyper D, Vanvoorden V, Madden C, Cioffi C, Peterson L, Blauvelt A. Bimekizumab versus Secukinumab in Plaque Psoriasis N Engl J Med. 2021 Jul 8;385(2):142-152.
- Glatt S, Baeten D, Baker T, Griffiths M, Ionescu L, Lawson ADG, Maroof A, Oliver R, Popa S, Strimenopoulou F, Vajjah P, Watling MIL, Yeremenko N, Miossec P, Shaw S. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation Ann Rheum Dis. 2018 Apr;77(4):523-532.
- Blair HA. Secukinumab: A Review in Ankylosing Spondylitis Drugs. 2019 Mar;79(4):433-443.
- Merola JF, Landew R, McInnes IB, Mease PJ, Ritchlin CT, Tanaka Y, Asahina A, Behrens F, Gladman DD, Gossec L, Gottlieb AB, Thai D, Warren RB, Ink B, Assudani D, Bajracharya R, Shende V, Coarse J, Coates LC. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor- inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE) Lancet. 2023 Jan 7;401(10370):38-48.
- Steere B, Beidler C, Martin A, Bright S, Kikly K, Benschop RJ. Generation and Characterization of Mirikizumab, a Humanized Monoclonal Antibody Targeting the p19 Subunit of IL-23 J Pharmacol Exp Ther. 2023 Nov;387(2):180-187.
- Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, Wehkamp J, Feagan BG, Yao MD, Karczewski M, Karczewski J, Pezous N, Bek S, Bruin G, Mellgard B, Berger C, Londei M, Bertolino AP, Tougas G, Travis SP; Secukinumab in Crohns Disease Study Group. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohns disease: unexpected results of a randomised, double-blind placebo-controlled trial Gut. 2012 Dec;61(12):1693-700.
- Brembilla NC, Senra L, Boehncke WH. The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond Front Immunol. 2018 Aug 2;9:1682.
